Unibest Unveils Innovative 505(b)(2) Project for Semaglutide: UB104 2025-04-16
In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.
Read More